Novavax NVAX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| Europe | $27.8M+119% | $15.74M-83.4% | $14.48M-91.0% | $15.64M-93.1% | $12.72M-95.7% | |
| Rest of the world | $106.24M+13.3% | $126.46M+110% | $112.37M+6.6% | $110.96M-29.5% | $93.81M-53.3% | |
| United States | $462.29M-18.7% | $405.61M-22.4% | $357.67M-37.3% | $371.99M-39.0% | $568.31M+74.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Novavax break its business down?
- Novavax (NVAX) reports development, tech transfer, launch, and sales milestone payments by product across 5 parts — Adjuvant Products Thereafter, CIC Product-Related Development Milestones, CIC Product-Related Launch Milestones, First Four Adjuvant Products and Licensed COVID-19 products and royalty payments. Each is extracted from the segment footnotes and tracked over time.
- Where does Novavax's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Novavax's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
